Skip to main content

AAV Vector manufacturing for diseases affecting very small populations

Food and Drug Administration

open
Rolling / OpenLast verified: 2026-07-05

About This Grant

CBER seeks to advance the development of gene therapies for diseases affecting very small populations, potentially even single individuals, by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors. Such innovations include the definition of critical quality attributes of AAV as vectors for gene therapy, development of advanced process analytics, development of a of non-proprietary AAV vectors, and demonstration of low-cost, non-proprietary GMP manufacturing methods for AAV vectors.This research will advance innovative manufacturing of AAV vectors for gene therapy. CBER anticipates that addressing the need for gene therapy products for diseases affecting very small populations will also lead to technical developments that will advance the entire field of gene therapy. Additionally, this research is intended to support advances in regulatory science that allow for development of science and risk-based guidelines to facilitate faster adoption of these innovative therapies. Some specific areas of research could include the following, but applications should clearly describe the potential impacts of the proposed enabling technology on readiness for broad implementation in the biological product industry, and/or regulatory evaluation: Definition of critical quality attributes of AAV vectors for gene therapy Development of advanced analytics to enhance AAV vector manufacturing process knowledge and monitoring of critical quality attributes Development of a non-proprietary suite of AAV vectors suitable for gene therapy applications for diseases affecting very small populations Demonstration of the feasibility of low-cost, non-proprietary GMP manufacturing methods for AAV vectors at a scale appropriate for very small populations (one batch provides approximately 5-20 doses)

Grant Summary

AAV Vector manufacturing for diseases affecting very small populations is a Food and Drug Administration grant providing up to $600K for municipality. Applications are accepted on a rolling basis. Check eligibility and apply with FindGrants.

Focus Areas

agriculturerural development

Eligibility

municipality

How to Apply

Funding Range

Up to $600K

Deadline

Rolling / Open

Complexity
Medium
  1. 1Confirm your organization is eligible for AAV Vector manufacturing for diseases affecting very small populations from Food and Drug Administration, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to Food and Drug Administration before the deadline.
Start Application

Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.

Don't want to draft it yourself?

We'll draft the complete application against Food and Drug Administration's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

AAV Vector manufacturing for diseases affecting very small populations: Frequently Asked Questions

Who is eligible for the AAV Vector manufacturing for diseases affecting very small populations?

AAV Vector manufacturing for diseases affecting very small populations is offered by Food and Drug Administration and is generally open to municipality. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the AAV Vector manufacturing for diseases affecting very small populations provide?

AAV Vector manufacturing for diseases affecting very small populations provides up to $600K per award from Food and Drug Administration. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the AAV Vector manufacturing for diseases affecting very small populations deadline?

AAV Vector manufacturing for diseases affecting very small populations accepts applications on a rolling or ongoing basis, so there is no single fixed deadline. Confirm current timing with the funder, Food and Drug Administration, before you apply, and submit as early as possible because rolling programs can close once funds are committed.

How do you apply for the AAV Vector manufacturing for diseases affecting very small populations?

To apply for AAV Vector manufacturing for diseases affecting very small populations, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from Food and Drug Administration.

Related Grants